Fulya Günşar

Fulya Günşar

Auto-generated profile, based on publicly available information

Fulya Günşar

Department of Gastroenterology, Ege University School of Medicine, Izmir, TURKEY

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MAMurat Akyildiz
Murat Akyildiz
FGFulya Gunsar
Fulya Gunsar
DNDeniz Nart
Deniz Nart
OSOsman Sahin
Osman Sahin
FYFunda Yılmaz
Funda Yılmaz
UAUlus Akarca
Ulus Akarca
Aim To investigate the macrophage migration inhibitory factor (MIF) expression and −173 G/C polymorphism of the MIF gene in nonalcoholic fatty liver disease (NAFLD). Method Ninety-one patients with diagnosis of NAFLD and 104 healthy controls were included in the study. MIF −173 G/C polymorphism was detected using the PCR–restriction fragment length polymorphism based method. NAFLD was stratified as nonalcoholic steatohepatitis (NASH), probable NASH and steatosis, respectively in groups 1, 2 and 3, according to NAFLD Activity Score. MIF expression was detected by immunohistochemistry staining. Results Mean age of the patients was 50.1±9.6 years, and 54 of them were male. Serum alanine aminotransferase and aspartate aminotransferase were 50/83, 42/63 and 31/32, respectively in groups 1, 2 and 3, (P<0.05). Both the MIF expression of hepatocytes and mononuclear cells were more prominent in groups 1 and 2 than group 3. There was no correlation between MIF expression of hepatocytes and fibrosis stage. However, MIF expression of mononuclear cells significantly increased according to fibrosis stage (P<0.05, R : 0.2). There was no significant correlation between MIF genotype and MIF expression in the liver. Conclusion MIF expression is significantly increased especially by mononuclear cells in liver tissue of patients with NASH secondary to inflammation. Thus, it should be considered as a consequence not a causal factor.

6 March 2014 in Liver International
Verified
Journal Article
Closed access
PDF file
GGGenco Gencdal
Genco Gencdal
FGFulya Gunsar
Fulya Gunsar
CMCenk E. Meral
Cenk E. Meral
ESEsin Salman
Esin Salman
BGBerna Gürsel
Berna Gürsel
UAUlus Salih Akarca
Ulus Salih Akarca

15 March 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
EÖErsan Özaslan
Ersan Özaslan
FGFulya Günşar
Fulya Günşar
AÖAslı Çiftçibaşı Örmeci
Aslı Çiftçibaşı Örmeci
IHİbRahim Hatemi
İbRahim Hatemi
CECumali Efe
Cumali Efe
RIRamazan İdIlman
Ramazan İdIlman
Autoimmune hepatitis (AIH) is a rare, immune-mediated liver disease. It has a heterogeneous nature with varied clinical presentations. The management of patients with AIH is challenging in many ways. The main difficulties are inexperience due to the rarity of the disease, diagnostic confusion in controversial areas such as variant/overlap cases, acute presentations, the presence of non-alcoholic fatty liver disease or drug-induced liver injury features, and the long and complex course of treatment. Here, we provide a clear, concise, and visualized review regarding the diagnosis and treatment of AIH, including illustrative cases.

15 November 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MZMurat Zeytunlu
Murat Zeytunlu
AUAlper Uguz
Alper Uguz
ÖÜÖmer Ünalp
Ömer Ünalp
OEOrkan Ergün
Orkan Ergün
ZKZeki Karasu
Zeki Karasu
NANurşen Altuğ
Nurşen Altuğ
Background/Aims: Liver transplantation (LT) is now the standard of care for most end-stage liver diseases. Over the next 30 years, advances in medicine and technology will greatly improve the survival rates of patients after this procedure. The aim of the present study was to analyze retrospectively the results of 1001 patients withLT. Materials and Methods: Medical reports of 989 patients were analyzed retrospectively. Data were obtained from the patient’s data chart. Descriptive statistics were used to describe continuous variables (mean, median, and standard deviation). Results: A total of 1001 LTs for 989 recipients were performed at Ege University Organ Transplantation and Research Center between 1994 and 2017. Therewere 639 male and 350 female recipients. Among 1001 LTs, there were 438 deceased donors and 563 living donors. The age interval of the patients was 4 months to 71 years old. The median Model for End-Stage Liver Disease score was 20. There were 12 deceased liver donors using the split method. There were 12 cases subject to retransplantation. In living donor LT grafts, 423 right lobes, 46 left lobes, and 94 left lateral sectors were used. In the first monitoring,the total annual mortality rate was 130 cases (13%). The mortality rate in retransplantation was found to be 66%. A 1-year survival rate of 87% was generally established. Conclusion: LThas been improving consistently over the last two decades. Ege University is one of the biggest liver transplant centers in Turkey for both technical and educational perspective. Cite this article as: Zeytunlu M, Uğuz A, Ünalp Ö, et al. Results of 1001 liver transplantations in 23 years: Ege University experience. Turk J Gastroenterol 2018; 29: 664-8.

1 January 2024 in Hepatology Forum
Verified
Journal Article
Open access
MAMesut Akarsu
Mesut Akarsu
SDSüleyman DOLU
Süleyman DOLU
MHMURAT HARPUTLUOGLU
MURAT HARPUTLUOGLU
SYSezai Yilmaz
Sezai Yilmaz
MAMurat Akyildiz
Murat Akyildiz
RIRamazan Idilman
Ramazan Idilman
Background and Aim: This study aimed to identify the indications for liv-er transplantation (LT) based on underlying etiology and to characterize the patients who underwent LT. Materials and Methods: We conducted a multicenter crosssectional ob-servational study across 11 tertiary centers in Turkiye from 2010 to 2020. The study included 5,080 adult patients. Results: The mean age of patients was 50.3±15.2 years, with a predominance of female patients (70%). Chronic viral hepatitis (46%) was the leading etiological factor, with Hepatitis B virus infection at 35%, followed by cryptogenic cirrhosis (24%), Hepatitis C virus infection (8%), and al-cohol-related liver disease (ALD) (6%). Post-2015, there was a significant increase in both the number of liver transplants and the proportion of living donor liver transplants (p

15 December 2020 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
TYTansu Yamazhan
Tansu Yamazhan
CACansu Bulut Avşar
Cansu Bulut Avşar
MZMurat Zeytunlu
Murat Zeytunlu
MTMeltem Taşbakan
Meltem Taşbakan
SSSaziye Ruchan Sertoz
Saziye Ruchan Sertoz
ZKZeki Karasu
Zeki Karasu
Background/Aims: Despite surgical advances in liver transplantation and effective prophylactic strategies, posttransplant infections are the most important cause of morbidity and mortality. Diagnosis and management of infections because of developing immunosuppression is difficult and adversely affects mortality. This study aimed to review bacterial and fungal infections in patients after liver transplantation and to reveal the resistance rates. Materials and Methods: A total of 107 patients who underwent liver transplantation between January 2017 and February 2018 were evaluated retrospectively with regard to demographic characteristics, causes of transplantation, conditions that may lead to infection, postoperative infections, pathogens, and resistance patterns. Results: Of the 107 patients who underwent liver transplantation, 48 (44.8%) had an infection. Bacterial infections were detected in 41% of the patients, and fungal infections were found in 13%. When we compared living and cadaveric transplants in terms of infection development, these rates were found to be 53% and 33%, respectively (p=0.034). No statistically significant results could be obtained when evaluating conditions such as sex, presence of underlying primary disease, Model for End-Stage Liver Disease MELD score, diabetes status, total parenteral nutrition, and risk factors for infection. Conclusion: After liver transplantation, infections are often seen in the first month of the postoperative period. Knowing the most common pathogens and resistance states in this process reduces infection-related deaths by providing appropriate treatment regimens at the right time.